Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry corresponds to a pseudogene of the MDM2 family, not the canonical E3 ubiquitin-protein ligase Mdm2 which plays a pivotal role in regulating p53, cell cycle, and tumorigenesis[1][2][3][4]. Pseudogenes are segments of DNA that resemble functional genes but typically do not produce functional proteins due to mutations or lack of regulatory sequences. The canonical Mdm2 protein is a validated therapeutic target in oncology due to its interaction with and regulation of p53, but the pseudogene does not contribute to these biological functions and is not considered a therapeutic target in itself. The functional MDM2 gene/protein (not the pseudogene) is a crucial oncogene, an E3 ubiquitin ligase that inhibits and promotes proteasomal degradation of p53, thus regulating cell cycle, apoptosis, and genomic stability. It is upregulated in various cancers and is a bona fide therapeutic target, with small molecule inhibitors like nutlins in clinical development[1][2][3][4]. However, these properties do not apply to the pseudogene encoded by ENSG00000223691.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mdm2, transformed 3T3 cell double minute 2, p53 binding protein pseudogene (MDM2 pseudogene).